Literature DB >> 18381406

Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome.

Uri Tabori1, David Malkin.   

Abstract

Germ-line mutations in specific genes predispose family members to cancer. Prediction of the exact tumor type and timing of cancer initiation is fundamental to the development of management strategies for these individuals. Recent advances in our understanding of the general processes that control cancer initiation may enable us to tailor more precise risk stratification. This, in turn, will lead to more effective early detection strategies, which would result in more favorable clinical outcomes. In this review, we highlight the steps and methods used to reach this futuristic model.

Entities:  

Mesh:

Year:  2008        PMID: 18381406     DOI: 10.1158/0008-5472.CAN-07-2091

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  p53, aerobic metabolism, and cancer.

Authors:  Cory U Lago; Ho Joong Sung; Wenzhe Ma; Ping-yuan Wang; Paul M Hwang
Journal:  Antioxid Redox Signal       Date:  2011-04-14       Impact factor: 8.401

2.  Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.

Authors:  Phuong L Mai; David Malkin; Judy E Garber; Joshua D Schiffman; Jeffrey N Weitzel; Louise C Strong; Oliver Wyss; Luana Locke; Von Means; Maria Isabel Achatz; Pierre Hainaut; Thierry Frebourg; D Gareth Evans; Eveline Bleiker; Andrea Patenaude; Katherine Schneider; Benjamin Wilfond; June A Peters; Paul M Hwang; James Ford; Uri Tabori; Simona Ognjanovic; Phillip A Dennis; Ingrid M Wentzensen; Mark H Greene; Joseph F Fraumeni; Sharon A Savage
Journal:  Cancer Genet       Date:  2012-08-29

Review 3.  Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician.

Authors:  Alexis Teplick; Megan Kowalski; Jaclyn A Biegel; Kim E Nichols
Journal:  Eur J Pediatr       Date:  2011-01-06       Impact factor: 3.183

Review 4.  Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis.

Authors:  Michael Safaee; Michael C Oh; Orin Bloch; Matthew Z Sun; Gurvinder Kaur; Kurtis I Auguste; Tarik Tihan; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-11-21       Impact factor: 12.300

Review 5.  Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Authors:  Erica L Carpenter; Yael P Mossé
Journal:  Nat Rev Clin Oncol       Date:  2012-05-15       Impact factor: 66.675

6.  At-risk populations for osteosarcoma: the syndromes and beyond.

Authors:  George T Calvert; R Lor Randall; Kevin B Jones; Lisa Cannon-Albright; Stephen Lessnick; Joshua D Schiffman
Journal:  Sarcoma       Date:  2012-03-12

7.  The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype.

Authors:  Marielle W G Ruijs; Annegien Broeks; Fred H Menko; Margreet G E M Ausems; Anja Wagner; Rogier Oldenburg; Hanne Meijers-Heijboer; Laura J van't Veer; Senno Verhoef
Journal:  Hered Cancer Clin Pract       Date:  2009-02-17       Impact factor: 2.857

8.  Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model.

Authors:  A Kathleen McClendon; Jeffry L Dean; Adam Ertel; Erik S Knudsen
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

9.  Breed-predispositions to cancer in pedigree dogs.

Authors:  Jane M Dobson
Journal:  ISRN Vet Sci       Date:  2013-01-17

10.  Predictive diagnosis of the cancer prone Li-Fraumeni syndrome by accident: new challenges through whole genome array testing.

Authors:  T Schwarzbraun; A C Obenauf; A Langmann; U Gruber-Sedlmayr; K Wagner; M R Speicher; P M Kroisel
Journal:  J Med Genet       Date:  2009-03-05       Impact factor: 6.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.